NCT02207257View on ClinicalTrials.gov

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

November 30, 2015

Conditions

Anticoagulation Reversal

Interventions

DRUG

PER977

Reversal of edoxaban-induced anticoagulation

DRUG

Placebo

Reversal of edoxaban-induced anticoagulation

DRUG

Edoxaban

Trial Locations (1)

66212

Quintiles, Overland Park

All Listed Sponsors

collaborator

Quintiles, Inc.

INDUSTRY

lead

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

INDUSTRY

NCT02207257 - Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban | Biotech Hunter | Biotech Hunter